Multiple other molecules (including combinations of entero-pancreatic hormones and oral GLP-1 RA) are in late phase clinical trials as potential obesity treatments, leading to WL that approaches the efficacy of bariatric surgery [101]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.